Q1 EPS Estimates for Haemonetics Decreased by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Equities researchers at Zacks Research reduced their Q1 2027 EPS estimates for shares of Haemonetics in a research report issued on Monday, October 6th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.18 for the quarter, down from their prior forecast of $1.19. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.36 EPS and FY2027 earnings at $5.21 EPS.

A number of other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $68.00 price target (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Raymond James Financial lowered shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Citigroup raised shares of Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 price objective for the company in a research note on Wednesday, July 9th. Finally, Robert W. Baird began coverage on Haemonetics in a research note on Thursday, June 26th. They set an “outperform” rating and a $87.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.78.

Haemonetics Stock Performance

NYSE:HAE opened at $49.63 on Tuesday. The firm has a market capitalization of $2.39 billion, a PE ratio of 15.18, a PEG ratio of 0.93 and a beta of 0.37. The stock’s fifty day moving average is $55.68 and its 200 day moving average is $63.57. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently made changes to their positions in the company. River Road Asset Management LLC increased its stake in shares of Haemonetics by 18.7% during the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after buying an additional 260,624 shares during the period. Geode Capital Management LLC grew its holdings in Haemonetics by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after acquiring an additional 23,257 shares in the last quarter. Royce & Associates LP increased its position in Haemonetics by 0.7% during the 1st quarter. Royce & Associates LP now owns 1,161,296 shares of the medical instruments supplier’s stock valued at $73,800,000 after purchasing an additional 8,028 shares during the period. Boston Trust Walden Corp raised its holdings in shares of Haemonetics by 22.1% in the 1st quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier’s stock valued at $71,070,000 after purchasing an additional 202,609 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Haemonetics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.